

Glucose 40%

Newborn use only

2024

Alert	40% glucose, on average, raises blood glucose by 0.4 mmol/L (95% CI -0.14–0.94) ² and should not be used alone in the treatment of moderate to severe hypoglycaemia. This can be a nurse-initiated medication according to the local hospital guideline. DO NOT squirt gel directly into the baby's mouth as this can cause choking
Indication	Prevention and treatment of hypoglycaemia in neonates ≥35 weeks' gestation and <48 hours of life ^{1,2}
Action	Glucose, a simple carbohydrate, in a concentrated aqueous gel solution can be administered by direct application to mucosal surfaces of the mouth, including buccal and lingual surfaces. Absorption from these sites may allow rapid access to the circulation. Some proportion of the dose may be swallowed and absorbed from the gastrointestinal tract. ²
Drug type	Glucose 40%.
Trade name	SugarBabies Gel (Biomed, New Zealand) Glucose15 Oral Glucose Gel – 15 g of glucose / 37.5 g tube.
Presentation	SugarBabies Gel (Biomed, New Zealand): Each 2.5 mL syringe contains Glucose (1 g), citric acid monohydrate, carmellose sodium, water. (TGA Listing 354150) Glucose15 Oral Glucose Gel – 15 g of glucose / 37.5 g tube. Lemon flavoured. Manufacturer does not recommend Glucose15 Gel under 2 years of age.
Dose	0.5 mL/kg/dose (200 mg/kg/dose). ³ Doses can be repeated as per the local hospital guidelines. 1 mL/kg/dose (400 mg/kg/dose) as a single dose has also been used. ⁵
Dose adjustment	Not applicable.
Maximum dose	Not more than 1.5 mL/kg. If no response, alternate measures to treat hypoglycaemia should be instituted.
Route	ORAL
Preparation	
Administration	This can be a nurse-initiated medication according to the local hospital guideline. 1. Wearing a clean glove, gently dry the infant's buccal mucosa with gauze. NOTE: If using tube, draw up required dose of gel slowly in an oral-only 5 mL syringe. 2. Dispense one-half of the dose from oral syringe onto gloved finger. 3. Massage into the buccal mucosa of one cheek. DO NOT SQUIRT DIRECTLY INTO BABY'S MOUTH. 4. Repeat with remaining half-dose inside the other cheek. 5. Large doses may be divided into 4 equal amounts and given alternating between cheeks. 6. Commence breastfeeding or administer expressed breast milk or formula. 7. Discard the unused portion of the gel.
Monitoring	Measure blood glucose 30 minutes after administration and subsequent management is as per the hospital guideline.
Contraindications	No information.
Precautions	<35 weeks gestation; infants at risk of aspiration or in whom feeds are contraindicated.
Drug interactions	No information.
Adverse reactions	Risk of aspiration if the gel is squirted directly into mouth.
Overdose	No specific recommendation.
Compatibility	No information.
Incompatibility	No information.
Stability	Single use product. Discard unused portion.
Storage	All preparations: Room Temperature <25°C
Excipients	SugarBabies Gel: Citric acid monohydrate, carmellose sodium, water. Glucose15 Oral Glucose Gel: Citric acid monohydrate, water, dextrose, glycerin, methylparaben, potassium sorbate, propylparaben, carboxymethylcellulose, sodium citrate.
Special comments	
Evidence	Prevention of neonatal hypoglycaemia Hegarty et al, in a systematic review, assessed the effectiveness and safety of oral dextrose gel in preventing hypoglycaemia among newborn infants at risk of hypoglycaemia and in reducing long-term neurodevelopmental impairment. They included one trial comparing oral dextrose gel versus placebo in 416 infants at risk of hypoglycaemia, most of whom were infants of diabetic mothers and were treated on the postnatal ward. Oral dextrose gel prophylaxis (any dose) was associated with reduced risk of hypoglycaemia compared with placebo (risk ratio (RR) 0.76, 95% confidence interval (CI) 0.62 to 0.94). There were no statistically significant differences in the number of adverse events, separation from mother for treatment of hypoglycaemia, exclusive breastfeeding at discharge or breastfeeding at six weeks postpartum. They concluded that oral dextrose gel reduced the risk of neonatal hypoglycaemia in at-risk

	infants with no statistically significant differences in the number of adverse events or in risk of separation of infant from mother for treatment of hypoglycaemia [LOE 1, GOR A] Treatment of neonatal hypoglycaemia Weston et al, in a systematic review, assessed the effectiveness of dextrose gel in correcting hypoglycaemia and in reducing long-term neurodevelopmental impairment in neonates at risk of hypoglycaemia.² They included two trials involving 312 infants. They found no significant difference between dextrose gel and placebo gel for major neurosensory disability at two-year follow-up (risk ratio (RR) 6.27, 95% confidence interval (CI) 0.77 to 51.03; one trial, n = 184; quality of evidence very low). Dextrose gel compared with placebo or no gel did not alter the need for intravenous treatment for hypoglycaemia (typical RR 0.78, 95% CI 0.46 to 1.32; two trials, 312 infants; quality of evidence very low). Infants treated with dextrose gel were less likely to be separated from their mothers for treatment of hypoglycaemia (RR 0.54, 95% CI 0.31 to 0.93; one trial, 237 infants; quality of evidence moderate) and were more likely to be exclusively breastfed after discharge (RR 1.10, 95% CI 1.01 to 1.18; one trial, 237 infants; quality of evidence moderate). Treatment of infants with neonatal hypoglycaemia with 40%dextrose gel reduces the incidence of mother-infant separation for treatment and increases the likelihood of full breast feeding after discharge compared with placebo gel. No excess adverse effects have been reported during the neonatal period or at two years' corrected age. Oral dextrose gel has not been compared to supplementary feeding with human milk or formula. Oral dextrose gel may be considered as first-line treatment for infants with neonatal hypoglycaemia. [LOE 1, GOR A]
Practice points	
References	- Hegarty JE, Harding JE, Crowther CA, Brown J, Alsweiler J. Oral dextrose gel to prevent hypoglycaemia in at-risk neonates. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012152. DOI: 10.1002/14651858.CD012152.pub2. - Weston PJ, Harris DL, Battin M, Brown J, Hegarty JE, Harding JE. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD011027. DOI: 10.1002/14651858.CD011027.pub2. - Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. Lancet 2013;382(9910):2077–83. - Harris D, Alsweiler J, Ansell J, Gamble G, Thompson B, Woudes T, et al. Outcome at 2 years after dextrose gel treatment for neonatal hypoglycaemia: follow-up of a randomized trial. Journal of Pediatrics 2016;170:54–9. - Troughton KEV, Corrigan NP, Tait RME. Hypostop gel in the treatment of neonatal hypoglycaemia: a randomised controlled trial. Archives of Disease in Childhood 2000;82 (Suppl 1):A30.

VERSION/NUMBER	DATE
Original 1.0	20/07/2018
Version 2.0	20/06/2019
Version 3.0	4/03/2024
Version 3.0 (Minor errata)	13/06/2024
Current 4.0	17/07/2025
REVIEW	17/07/2030

Authors Contribution for the current version

Author/s	Srinivas Bolisetty, Nilkant Phad
Evidence Review	David Osborn
Pharmacy Review	Rebecca O'Grady, Thao Tran
Nursing Review	Eszter Jozsa, Bryony Malloy
ANMF Group contributors	Bhaves Mehta, Rebecca Barzegar, Mohammad Irfan Azeem, Rebecca O'Grady, Cindy Chen, Thao Tran, Celia Cunha Brites, Kerrie Knox, Susannah Brew, Bryony Malloy, Renae Gengaroli, Samantha Hassall, Jutta van den Boom, Amber Seigel, Tiffany Kwan, Charles Tian, Emma Watson
Final editing	Srinivas Bolisetty
Electronic version	Thao Tran, Helen Huynh, Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty

Citation for the current version

Bolisetty S, Osborn D, O'Grady R, Tran T, Phad N, Mehta B, Barzegar R, Kluckow M, Azeem MI, Jozsa E, Malloy B, Jenkins M, Chen C, Huynh H, Brew S, Kaur S, Halena S, Emerson-Parker B, Gengaroli R, Houghton K, Callander I. Glucose 40%. Consensus formulary by the Australasian Neonatal Medicines Formulary group. Version 3. Dated 4 March 2023. www.anmfonline.org

NEW RELEASE